Helius Medical Technologies, Inc. (HSDT)
NASDAQ: HSDT · Real-Time Price · USD
1.090
-0.050 (-4.39%)
At close: Jun 6, 2025, 4:00 PM
1.120
+0.030 (2.75%)
After-hours: Jun 6, 2025, 7:40 PM EDT
HSDT Revenue
Helius Medical Technologies had revenue of $49.00K in the quarter ending March 31, 2025, a decrease of -63.70%. This brings the company's revenue in the last twelve months to $434.00K, down -35.03% year-over-year. In the year 2024, Helius Medical Technologies had annual revenue of $520.00K, down -19.25%.
Revenue (ttm)
$434.00K
Revenue Growth
-35.03%
P/S Ratio
0.74
Revenue / Employee
$20,667
Employees
21
Market Cap
575.59K
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 520.00K | -124.00K | -19.25% |
| Dec 31, 2023 | 644.00K | -143.00K | -18.17% |
| Dec 31, 2022 | 787.00K | 265.00K | 50.77% |
| Dec 31, 2021 | 522.00K | -139.00K | -21.03% |
| Dec 31, 2020 | 661.00K | -835.00K | -55.82% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.98B |
| Novartis AG | 53.22B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
HSDT News
- 1 day ago - Helius Medical Technologies Announces Pricing of $9.1 Million Public Offering - GlobeNewsWire
- 2 days ago - Helius Medical Technologies, Inc. Compliant with Nasdaq Bid Price Rule Listing Criteria - GlobeNewsWire
- 17 days ago - Helius to Spotlight Study Confirming Improved Long-Term Outcomes from Adherence to PoNS Therapy® at CMSC Annual Meeting - GlobeNewsWire
- 25 days ago - Helius Medical Technologies, Inc. Announces Reimbursement by Major Healthcare Provider for its Portable Neuromodulation Stimulator (PoNS®) Device - GlobeNewsWire
- 5 weeks ago - Helius Medical Technologies Announces Reverse Stock Split - GlobeNewsWire
- 3 months ago - Helius Medical Technologies, Inc. Announces the Establishment of a Wholly Owned Brain Computer Interface (“BCI”) Technology Private Subsidiary - GlobeNewsWire
- 3 months ago - Helius Medical Technologies, Inc. Announces First Reimbursement by A Major Healthcare Provider for its Portable Neuromodulation Stimulator (PoNS®) Device - GlobeNewsWire
- 4 months ago - Helius Medical Technologies, Inc. Announces First Clinical Evidence of Positive Long-term Therapeutic Effects of PoNS Therapy® on Gait Deficit Improvement in Multiple Sclerosis from the PoNS® Therapeutic Experience Program Study - GlobeNewsWire